Due to the relatively low frequency of BRCA1/2 mutations, this limits their applicability to the treatment of 10–15% of breast and ovarian tumors, 4–7% of pancreatic tumors and 1.5% of prostate carcinoma (Bryant et al., 2005; Iqbal et al., 2012; Oh et al., 2019). Here, BRCA1 is linked to pancreatic neoplasm.